Journal: British Journal of Pharmacology

Article Title: Low‐concentration DMSO accelerates skin wound healing by Akt / mTOR ‐mediated cell proliferation and migration in diabetic mice

doi: 10.1111/bph.15052

Figure Lengend Snippet: DMSO promotes the migration of diabetic mouse‐derived primary keratinocytes in an indirect manner mediated by fibroblast‐derived TGF‐β1. (a) Migration of the keratinocytes by transwell assays after treatment with or without 5‐mM DMSO or TGF‐β1 for 24 h. Data are presented as the mean ± SEM with n = 5 for all groups, analysed by one‐way ANOVA with Kruskal–Wallis test for multiple comparison. Significance level: *P < 0.05, compared with the control group. NS, not significant. (b) Representative H&E‐stained sections of wound tissue 8 days after injury. The arrow indicates the length of the migrating epithelial tongue. Data are presented as the mean ± SEM with n = 6 for all groups, analysed by Student's t test. Significance level: *P < 0.05, 5‐mM DMSO versus the control group. Scale bars represent 100 μm; original magnification ×100. (c) Immunofluorescence staining of TGF‐β1 in DMSO‐treated and untreated wound tissue (n = 6). Scale bars represent 50 μm; original magnification ×200. (d) Migration of keratinocytes treated as indicated. MF, cocultured with mouse fibroblasts by a transwell assay; 1D11, a TGF‐β1 neutralizing antibody. Data are presented as the mean ± SEM with n = 5 for all groups, analysed by one‐way ANOVA with Kruskal–Wallis test for multiple comparison. Significance level: *P < 0.05, compared with the MF group, (e) western blot of migration‐related proteins in the keratinocytes treated as indicated

Article Snippet: According to the stimulants added to the medium in the bottom chamber, six experimental groups were established: PBS control, DMSO (5 mM), recombinant mouse TGF‐β1 (5 ng·ml −1 , R&D Systems, Minnesota, USA), mouse fibroblasts (MFs, 4 × 10 5 cells), MF + DMSO and MF + DMSO+1D11 (a TGF‐β1 (TGFBR1) neutralizing antibody, 10 g·ml −1 , R&D Systems, Minnesota, USA).

Techniques: Migration, Derivative Assay, Staining, Immunofluorescence, Transwell Assay, Western Blot

Journal: Molecular Metabolism

Article Title: mTORC1-dependent increase in oxidative metabolism in POMC neurons regulates food intake and action of leptin

doi: 10.1016/j.molmet.2018.04.002

Figure Lengend Snippet: Central administration of the ROS H 2 O 2 engages mTORC1 signaling to decrease food intake. ( A ) Acute icv co-administration of the mTORC1 inhibitor rapamycin with H 2 O 2 blunts the effect of H 2 O 2 on food intake (Repeated measures ANOVA: treatment effect F (2,15) = 6.39, P < 0.01; time effect F (3,45) = 141.33, P < 0.0001; treatment × time interaction F (6,45) = 4.59, P < 0.01, n = 5–7 mice per group) and ( B ) 24h body weight (BW) change (One-way ANOVA: treatment effect F (2,15) = 9.37, P < 0.005, n = 5–7 mice per group) in C57BL/6J mice. ( C ) Effect of an acute icv administration of H 2 O 2 on food intake (Repeated measures ANOVA: treatment effect F (1,40) = 7.94, P < 0.01; genotype effect F (1,40) = 11.24, P < 0.005; treatment × genotype interaction F (1,40) = 6.18, P < 0.05; time effect F (3,120) = 892.17, P < 0.0001; treatment x genotype × time interaction F (3,120) = 7.58, P < 0.0005, n = 10–12 mice per group) and ( D ) 24h BW change (two-way ANOVA: treatment effect F (1,40) = 5.71, P < 0.05; genotype effect F (1,40) = 4.37, P < 0.05; treatment × genotype interaction F (1,40) = 9.81, P < 0.005, n = 10–12 mice per group) in WT and S6K1 -KO littermates. Data are mean ± SEM. *P < 0.05, **P < 0.005, ***P < 0.0005.

Article Snippet: To study the effect of a central mTORC1 inhibition on the appetite suppressant action of H 2 O 2 , mice received an acute icv injection of rapamycin [VWR International, France; 18 μg in 1 μL dimethyl sulfoxide (DMSO)], an inhibitor of mTORC1 , or its vehicle just before the dark phase, 40 min after an acute icv injection of H 2 O 2 in 24h fasted C57BL/6J mice.

Techniques:

Journal: Frontiers in Immunology

Article Title: Retinal response to systemic inflammation differs between sexes and neurons

doi: 10.3389/fimmu.2024.1340013

Figure Lengend Snippet: Antagonism of TNFR1 and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.

Article Snippet: Madrid, Spain] and TNFR1 antagonist [12 mg/kg i.p. in 5% of DMSO-saline; R7050, Tocris Bioscience; Bio-Techne R&D Systems, Madrid, Spain], as previously published , were both injected intraperitoneally in a final volume of 200 μL.

Techniques: Injection, Comparison

Journal: Frontiers in Immunology

Article Title: Retinal response to systemic inflammation differs between sexes and neurons

doi: 10.3389/fimmu.2024.1340013

Figure Lengend Snippet: Transient impairment of retinal functionality after systemic inflammation: effect of TNFR1 and P2X7R antagonism. (A) Electroretinographic waves from female and male mice recorded before (PRE) and 3 and 7 days after being treated with LPS + vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. (B) ERG quantification bar graphs showing the mean wave amplitude (µV ± SD). Control amplitudes are baseline recordings (pre). * vs. baseline values (* p <0.05; ** p <0.01***; p <0.001; **** p <0.0001); φ 3 rd vs. 7 th day within the same group ( φφφ p <0.001; φφφφ p <0.0001). σ Between different groups ( σ p <0.05; σσ p <0.01; σσσ p <0.001; σσσσ p <0.0001). † p <0.001 females vs. males at the same time point and treatment. Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p >0.05).

Article Snippet: Madrid, Spain] and TNFR1 antagonist [12 mg/kg i.p. in 5% of DMSO-saline; R7050, Tocris Bioscience; Bio-Techne R&D Systems, Madrid, Spain], as previously published , were both injected intraperitoneally in a final volume of 200 μL.

Techniques: Control, Comparison